All In Biotech

Drug Trial Radar · NCT00221000

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis

A Phase II, Multicenter, Randomized, Double-blind, "Sham" Pheresis-controlled, Study of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis in Patients Who Have an Inadequate Response to Disease Modifying Antirheumatic Drugs and Biological Agents

Last checked: Nov 20, 2026Latest source record: Oct 19, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

86

Actual

Start

Aug 2003

Primary completion

Oct 2006

Study completion Nov 2006

Sponsor

Lead sponsor
MallinckrodtIndustry
Sponsor type
Industry
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disorder that can cause substantial pain and joint tenderness, significant joint damage, and serious disability. The treatment goals are minimization of the signs and symptoms of the disease, and the reduction of irreversible joint damage. As the understanding of the pathophysiological mechanisms underlying RA is elucidated, the opportunity to target specific inflammatory processes with new therapies has improved. Rheumatoid arthritis is a T cell-mediated autoimmune disease and there are various therapies, including newer experimental therapies, which target either the activation of T cells or the neutralization of their effector mechanisms. These newer therapies have shown benefit in human and animal models of RA. Extracorporeal photoimmune therapy (ECP) has been shown to be safe and effective in the palliative treatment of the skin manifestations of cutaneous T cell lymphoma. Experimental studies have also demonstrated activity of ECP treatment in several T cell mediated diseases including graft versus-host disease, rejection after organ transplantation, and selected autoimmune diseases. This study will evaluate a cell-based therapy (ECP) in patients who have an inadequate response to disease-modifying antirheumatic drugs (DMARDs) and biological agents to determine if ECP treatment can reduce the signs and symptoms of RA in this refractory patient population.

Conditions

  • Rheumatoid Arthritis

Interventions

  • MethoxsalenDrug

  • Extracorporeal PhotopheresisProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ACR 20Time frame: week 24 and week 28

Locations

32 sites in 11 countries. Site status is shown where the registry gives one.

  • Carroll County Arthritis and Osteoporosis Center

    Westminister, Maryland

  • Clinical Pharmacology Study Group

    Worchester, Massachusetts

  • Morristown Memorial Hospital

    Morristown, New Jersey

  • AAIR Research Center

    Rochester, New York

  • Carolina Arthritis Associates

    Wilmington, North Carolina

  • Rheumatic Disease Associates

    Willow Grove, Pennsylvania

  • Rheumatology Associates

    Providence, Rhode Island

  • UT Southwestern Medical Center

    Dallas, Texas

  • Arthritis and Osteoporosis Center of South Texas

    San Antonio, Texas

  • Benaroya Research Institute at Virginia Mason

    Seattle, Washington

  • Royal Brisbane Hospital

    Herston, Australia

  • General Hospital of Vienna

    Vienna, Austria

  • Hospital Brugmann

    Brussels, Belgium

  • Limburgs Universitair Centrum

    Diepenbeek, Belgium

  • Rebecca MacDonald Centre for Arthritis

    Toronto, Ontario, Canada

  • CHRU de Lille

    Lille, France

  • Hopital Edouard Herriot

    Lyon, France

  • Franz von Prummer Klinik

    Bad Brückenau, Germany

  • University of Charite Clinic for Rheumatology and Immunology

    Berlin, Germany

  • Klinikum der Universitat zu Koln

    Cologne, Germany

  • Medizinische Klinik III

    Erlangen, Germany

  • Abt. Rheumatologie und Klinische Immunologie

    Hamburg, Germany

  • Westfalische wilhelms-universitat Munster

    Münster, Germany

  • Medizinische Klinik des Evangelischen Kranken

    Oldenburg, Germany

  • Universita degli Studi di Firenze

    Florence, Italy

  • Universita de Genova - Ospedale S. Martino

    Genova, Italy

  • University of Siena-Italy

    Siena, Italy

  • OPD- Hospital Civil "Dr. Jaun I. Menchaca"

    Guadalajara, Jalisco, Mexico

  • Reumatologicka ambulancia, Polinika

    Bratislava, Slovakia

  • South African National Blood Service

    Bloemfontein, South Africa

  • Christian Barnard Mermorial Hospital

    Cape Town, South Africa

  • D6 Rheumatology Clinic and E5 Hematology Unit

    Cape Town, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.